Clinical blood pool MR imaging
暂无分享,去创建一个
Martin Rohrer | Tim Leiner | M. Goyen | T. Leiner | M. Rohrer | S. Schönberg | Mathias Goyen | Stefan Schönberg
[1] W. Heindel,et al. First‐pass and equilibrium‐MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study , 2004, NMR in biomedicine.
[2] Debiao Li,et al. Contrast-enhanced MR imaging of coronary arteries: comparison of intra- and extravascular contrast agents in swine. , 2001, Radiology.
[3] Peter Caravan,et al. Species Dependence on Plasma Protein Binding and Relaxivity of the Gadolinium-Based MRI Contrast Agent MS-325 , 2006, Investigative radiology.
[4] J. Mintorovitch,et al. Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.
[5] S. Schoenberg,et al. Vasovist-enhanced MR angiography , 2006, European radiology.
[6] S. Schoenberg,et al. High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. , 2006, Radiology.
[7] Jayaram K. Udupa,et al. Artery-vein separation via MRA-An image processing approach , 2001, IEEE Transactions on Medical Imaging.
[8] M. Knopp,et al. Assessment of Utilization and Pharmacovigilance Based on Spontaneous Adverse Event Reporting of Gadopentetate Dimeglumine as a Magnetic Resonance Contrast Agent After 45 Million Administrations and 15 Years of Clinical Use , 2006, Investigative radiology.
[9] Yoshimi Anzai,et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent , 1997, Journal of magnetic resonance imaging : JMRI.
[10] R. Muller,et al. Paramagnetic liposomes as magnetic resonance imaging contrast agents. Assessment of contrast efficacy in various liver models. , 1998, Investigative radiology.
[11] R. Lauffer,et al. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. , 1997, Investigative radiology.
[12] R. Lauffer,et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.
[13] A. Nunn,et al. Can receptors be imaged with MRI agents? , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[14] B. Misselwitz,et al. Interstitial Magnetic Resonance Lymphography Using a Polymeric T1 Contrast Agent: Initial Experience With Gadomer-17 , 2002, Investigative radiology.
[15] V. Jacques,et al. New Classes of MRI Contrast Agents , 2002 .
[16] Nicolaas Bloembergen,et al. Proton Relaxation Times in Paramagnetic Solutions. Effects of Electron Spin Relaxation , 1961 .
[17] S. F. Quinn,et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography--multicenter comparative phase III study. , 2005, Radiology.
[18] L. Calabi,et al. The problematic determination of proton magnetic relaxation rates of protein-containing solutions. , 2002, Academic radiology.
[19] J Lautrou,et al. Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. , 2001, Investigative radiology.
[20] M. Port,et al. P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.
[21] B. Rutt,et al. Comparison of two blood pool contrast agents for 0.5-T MR angiography: experimental study in rabbits. , 2000, Radiology.
[22] B. Hamm,et al. Phase I Clinical Evaluation of Citrate-coated Monocrystalline Very Small Superparamagnetic Iron Oxide Particles as a New Contrast Medium for Magnetic Resonance Imaging , 2004, Investigative radiology.
[23] I. Bertini,et al. Nuclear and Electron Relaxation: The Magnetic Nucleus-Unpaired Electron Coupling in Solution , 1991 .
[24] Wolfgang Ebert,et al. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.
[25] A. Bjørnerud,et al. NC100150 injection, a preparation of optimized iron oxide nanoparticles for positive‐contrast MR angiography , 2000, Journal of magnetic resonance imaging : JMRI.
[26] Tim Leiner,et al. Maximizing contrast‐to‐noise ratio in ultra‐high resolution peripheral MR angiography using a blood pool agent and parallel imaging , 2007, Journal of magnetic resonance imaging : JMRI.
[27] A. Wiethoff,et al. Initial imaging recommendations for Vasovist angiography , 2006, European radiology.
[28] Peter Caravan,et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. , 2002, Journal of the American Chemical Society.
[29] Weissleder,et al. Approaches and agents for imaging the vascular system. , 1999, Advanced drug delivery reviews.
[30] R. Lauffer,et al. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design , 1987 .
[31] D C Peters,et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. , 1998, Radiology.
[32] R. Lauffer,et al. Targeted relaxation enhancement agents for MRI , 1991, Magnetic resonance in medicine.
[33] I. Bertini,et al. NMR of paramagnetic substances , 1996 .
[34] M. Port,et al. How to Compare the Efficiency of Albumin-Bound and Nonalbumin-Bound Contrast Agents In Vivo: The Concept of Dynamic Relaxivity , 2005, Investigative radiology.
[35] T. Steger-Hartmann,et al. Preclinical Safety Assessment of Vasovist (Gadofosveset trisodium), a New Magnetic Resonance Imaging Contrast Agent for Angiography , 2006, Investigative radiology.